Characteristics Of Lung Cancer Patients Research Articles

Transcription factor SP1 and oncoprotein PPP1R13L regulate nicotine-induced epithelial-mesenchymal transition in lung adenocarcinoma via a feedback loop

Tobacco remains the most common environmental carcinogen leading to the occurrence and development of lung cancer. Nicotine, a tumor promoter in cigarette smoke, has been shown to induce epithelial-mesenchymal transition (EMT), a cellular program required for the invasion and metastasis in tumor cells. Specificity Protein 1 (SP1) is a well-characterized transcription factor that can regulate the EMT process via transcriptionally activating E-cadherin expression. Protein Phosphatase 1 Regulatory Subunit 13 Like (PPP1R13L) is a newly identified oncoprotein previously reported to inhibit the transcriptional activity of SP1 via a direct protein–protein interaction. To reveal the underlying implication of the interconnections between PPP1R13L and SP1 in the nicotine-induced EMT process, the present study established an EMT cell model of lung cancer using 1 μM of nicotine, a dose close to human exposure, in which an alternate fluctuation in the expression of PPP1R13L and SP1 was captured. Subsequently, the direct inhibition of SP1 by PPP1R13L was demonstrated to be a critical mechanism underlying the involvement of PPP1R13L in the nicotine-induced EMT process. More interestingly, SP1 was further shown to transcriptionally activate PPP1R13L expression in a feedback manner. In addition, PPP1R13L and SP1 expression was found to be closely associated with the clinicopathological characteristics of lung cancer patients. Here we proposed a novel feedback regulation mechanism, in which SP1 may transcriptionally activate the PPP1R13L gene expression in the early stage of lung cancer to promote tumor growth, while the accumulation of PPP1R13L drives tumor invasion and metastasis by direct repression of SP1. Thus, this unique feedback loop between PPP1R13L and SP1 may play a vital role in chemical carcinogenesis and serve as a potential intervention target for lung cancer progression attributable to cigarette smoking.

Predicting the prevalence of lung cancer using feature transformation techniques

Healthcare sector is one of the most important sectors of any country as a big part of the country’s economy is associated with it. The research is about to contribute to the health sector by minimizing the expenses of a lung cancer diagnosis. The study tries to devise an efficient method for initial screening of the patients with symptoms through their demographic and clinical data. The study seeks appropriate feature transformation techniques from dimensionality reduction techniques in combination with an apposite regression model that can perform this task robustly using the lung cancer dataset for early carcinoma diagnosis. To equip the health sector with state-of-the-art technology and for the betterment of humankind, the most beneficial tool of today is machine learning. Lungs play a vivacious role in the human body, oxygen is circulated in the body, and the air is taken from the atmosphere and sends it into the bloodstream. Several people decease every year because of lung carcinoma as lung cancer is normally identified at the latter phase due to lack of awareness. It stays unidentified because people have pneumonia often, which converts into lung cancer later. The projected research seeks to enable health professionals to the rationalization of primary diagnosis and treatment of lung carcinoma in developing countries. The proposed methodology has selected the optimized combination of regression-based machine learning technique and feature transformation technique for the available patterns based on demographic and clinical features of lung cancer patients. Based on the gathered results during training (RMSE = 0.1324, R2-Score = 0.7428) and testing (RMSE = 0.1273, R2-Score = 0.7405) it can be concluded that the fast independent component analysis and elastic net regression technique provided optimized results and outperform the other aspirant techniques.

Assessment of lung cancer patient’s satisfaction with universal health insurance at Port Said Governorate

Background: Lung cancer is a type of cancer that begins in the lung. Assessing the level of satisfaction provides actionable insights to improve the healthcare system. Egypt is embarking on a new Universal Health Insurance system (UHIS) to cover all Egyptians by 2032. Aim of the study: The present study aimed to assess lung cancer patient’s satisfaction with universal health Insurance at Port Said Governorate. Design: A descriptive research design was utilized to conduct this study. Sample: A purposive sample used in this study. Sample size: 136 lung cancer patients. Setting: Study conducted at oncology outpatient clinic El Tadamon Specialized Hospital at Port Said Governorate. Tool: An interviewing questionnaire tool divided to two parts, Part1: Consists of A- Socio-demographic characteristics of lung cancer patients, B- Universal health insurance utilization of lung cancer patients, Part II: Patients’ satisfaction adopted tool which contain 7 domains obtained from (Phaswana et al.,2011). Results: The study results revealed that 48.5% of studied lung cancer patients were had moderate level of satisfaction related to their total patient satisfaction. While, 33.8% of them were had high level of satisfaction & 17.7% of studied sample were had low level of satisfaction related their total patient satisfaction.

Evaluation of Lung Cancer Patients Treated with Supportive Care Alone

Among lung cancer patients, receiving supportive care alone is not rare. However, the clinical characteristics of these patients were not thoroughly studied. The purpose of this study is to investigate the clinical characteristics of lung cancer patients treated with supportive care alone. We retrospectively analysed the rate of lung cancer patients receiving supportive care alone in 3 separate hospitals, along with the reasons for this practice. Additionally, we investigated the histological types, palliative treatment forms, hospital consultation outcomes and places of death. A total of 611 patients were diagnosed with lung cancer from April 2016 to March 2022. 80 (13%) were treated with supportive care alone. The primary reason underlying treatment with supportive care alone in almost half of the patients was poor performance. In general, 40% of the patients received supportive care and 17% were admitted to a palliative care unit. 17% of the patients died at home and 42% in the palliative care unit. This study has revealed that 13% of the lung cancer patients with cytologic diagnoses are treated with supportive care alone, due to poor performance. 40% of these patients received supportive care at home, showing that a more accessible home care system is required for the patients and their families.

Research Progress of Pharmacological Therapy and Nutritional Support for Cachexia in Lung Cancer Patients

恶病质是肺癌患者的一种常见并发症，它会加重化疗毒副作用、阻碍治疗计划、削弱化疗反应性、降低生活质量，增加并发症及死亡率，严重危害肺癌患者的生理、心理健康。肿瘤恶病质的发病原因与发病机制都极为复杂，使其治疗具有艰巨性与复杂性。控制肺癌患者的恶病质需要采取抗肿瘤治疗、抑制炎症反应、营养支持、体育锻炼、缓解症状等多种手段，发挥多模式治疗的协同作用对抗肿瘤恶病质的多种机制。迄今为止，学科内已就任何单一疗法都不能控制恶病质的发生发展达成了一致共识。有些疗法取得了一定的研究进展，但需要在充分评估肺癌患者个体特征后结合多模式治疗实施。本文重点综述了肿瘤恶病质的药物治疗与营养支持等干预方法在肺癌患者人群中的应用，并对肺癌患者恶病质控制的研究方向进行展望。

Abstract 5992: Clonal evolutionary molecular mechanism of lymphatic metastasis in lung cancer

Abstract Background: Lung cancer approximately accounts for more than a third of cancers, approximately 787,000 in China annually, which the death rate is greatest and most lethal in all cancers. However, clonal evolutionary molecular mechanism of lymphatic metastasis in lung cancer remains largely unknown according to previously reported. Methods: In this study, we systematically analyzed clonal evolution of 21 primary patients paired with lymphatic metastasis based on 500 gene-panel target sequencing and clinical characters. The two pipelines were performed to identify the subclones between primary and lymphatic metastasis on each patient, one is Pyclone, citup and Timespace, another is sciClone and clonevol. Furthermore, the genes associated with clonal evolutions were verified to be differentially mutated genes between primary and lymphatic metastasis in MSK-IMPACT 2017 cohort by fisher-test (P < 0.05). Results: The clonal clusters were explored in 3 of 21 patients (P08, P52, P57) with lung cancer by first pipeline, and 4 (P02, P08, P14 and P84) by second pipeline. The 2 genes TET2 and BRCA2 were identified to be associated with lymphatic metastasis. The mutation frequency of TET2 and BRCA2 were 4.2% and 7.1% in patients with lymphatic metastasis in validation cohort. Conclusions: We described molecular features of lung cancer patients with lymphatic metastasis. TET2 and BRCA2 mutations promoted development and evolution of tumor cells, which were insightful for developing novel therapeutic strategies to inhibit the progress of tumors. Keywords: Clonal Evolutionary, Molecular Mechanism, Lymphatic Metastasis, Lung cancer Citation Format: Nanan Guo, Hongmei Zhao. Clonal evolutionary molecular mechanism of lymphatic metastasis in lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5992.

Demography and Characteristics of Lung Cancer Patients Evaluated by 18F-FDG PET- CT imaging - Retrospective Analysis in NINMAS

Introduction: Carcinoma of the lung is one of the most common cancer in Bangladesh. Fluorine-18-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET-CT) plays an important role in staging and evaluating therapy response. Currently, limited data is available about the demography and characteristics of lung cancer patients in Bangladesh by 18F-FDG PET-CT scan. Objectives: To evaluate the demographic pattern and pattern of findings in lung cancer patients by 18F-FDG PET-CT scan in the National Institute of Nuclear Medicine and Allied Sciences (NINMAS), Dhaka. Materials and Methods: This retrospective study was conducted in the PET-CT division of NINMAS. A total of 53 patients out of 103 patients with lung cancer were enrolled who were referred to NINMAS from October 2020 to December 2021 for either baseline PET CT or for assessment of therapy response. Data were collected in a predesigned format from old documents and analyzed for demographic characteristics, histopathologic, morphologic and metabolic patterns as well as a comparison of the overall number of lung cancer patients with previous years. Results: Among the enrolled 53 lung cancer patients the majority (34%) are in the 6th to 7th decades with 56.6% male and 43.4 % female. Adenocarcinoma (62%) and squamous cell carcinoma (24%) were the most common lung cancer subtypes. The majority of patients (53%) came for a therapeutic response evaluation; among them, 32% had a good response following therapy, 25% with progressive disease and others had mixed response, partial response, and stable disease. Nine percent of the patients came for follow up and among them, recurrence is detected in 20%. Lung cancer patients who came for baseline study, (38%) were upstaged (80%) mainly with 20% remaining in the same stage. Conclusion: The demographic pattern of lung cancer patients observed in this study belonged to 6th & 7th decades having male predominance. Most of the patients were diagnosed with advanced stages of lung cancer. The use of 18FDG PET-CT is crucial for the staging and diagnosis of suspected lung cancer, as well as therapeutic response and follow-up. Bangladesh J. Nuclear Med. 25(1): 22-27, 2022

Unique characteristics of G719X and S768I compound double mutations of epidermal growth factor receptor (EGFR) gene in lung cancer of coal-producing areas of East Yunnan in Southwestern China

BackgroundThe principal objective of this project was to investigate the Epidermal Growth Factor Receptor (EGFR) gene mutation characteristics of lung cancer patients, which can provide a molecular basis for explaining the clinicopathological features, epidemiology and use of targeted therapy in lung cancer patients in the coal-producing areas of East Yunnan.MethodologyWe collected 864 pathologically confirmed lung cancer patients’ specimens in First People’s Hospital of Qujing City of Yunnan Province from September 2016 to September 2021. We thereafter employed Next Generation Sequencing (NGS) technology to detect all exons present in the EGFR gene.ResultsThe overall mutation frequency of the EGFR gene was 47.22%. The frequency of EGFR gene mutations in the tissue, plasma, and cytology samples were found to be 53.40%, 23.33%, and 62.50%, respectively. Univariate analysis indicated that the coal-producing areas and Fuyuan county origin were significantly associated with relatively low EGFR gene mutation frequency. Female, non-smoking history, adenocarcinoma, non-brain metastasis, and tissue specimens were found to be related to high EGFR gene mutation frequency. Multivariate logistic regression analysis suggested the lung cancer patients in the central area of Qujing City, stage Ia, non-coal-producing areas, non-Fuyuan origin, and non-Xuanwei origin were more likely to develop EGFR gene mutations. The most common mutations were L858R point mutation (33.09%) and exon 19 deletion (19-del) (21.32%). Interestingly, the mutation frequency of G719X (p = 0.001) and G719X + S768I (p = 0.000) in the coal-producing areas were noted to be more significant than those in non-coal-producing regions.ConclusionThis findings of this study might be important in establishing the correlation between routine using NGS for EGFR gene mutation diagnosis and clinical practice in the lung cancer patients.

Characteristics of patients with lung cancer in clinical practice and their potential eligibility for clinical trials evaluating tyrosine kinase inhibitors or immune checkpoint inhibitors

IntroductionIn- and exclusion criteria of randomized clinical trials (RCTs) aim to include a homogeneous study-population. This study compared characteristics of lung cancer patients from phase III RCTs evaluating tyrosine kinase inhibitors (TKIs) or immune checkpoint inhibitors (ICIs) with characteristics of lung cancer patients in a real world setting in the United Kingdom. MethodsA retrospective study was conducted using the Clinical Practice Research Datalink GOLD. Patients (N = 9239) with a first ever lung cancer registration between 2014 and 2018 were identified. Eligibility for inclusion was assessed for twelve RCTs (evaluating TKIs or ICIs). Reasons for potential exclusion and the number of unmet criteria were assessed for each RCT independently. OS was assessed using Kaplan-Meier and Cox proportional hazards analyses. ResultsThe proportion of potentially eligible patients was 74.3% and 51.9% for TKI and ICI RCTs, respectively. History of another malignancy, renal insufficiency or concomitant drug-use were main reasons for exclusion. OS was considerably longer for potentially eligible patients. Hazards ratios varied from 1.17 (95% confidence interval, 1.11–1.24) to 1.35 (1.20–1.42) across the RCTs. ConclusionThis study showed that a considerable proportion of lung cancer patients in a real-world setting would have been ineligible for participation in phase III RCTs and that potentially ineligible patients experienced a shorter OS.

Lymphocyte percentage as a valuable predictor of prognosis in lung cancer.

Lymphocytes and neutrophils are involved in the immune response against cancer. This study aimed to investigate the relationship between lymphocyte percentage/neutrophil percentage and the clinical characteristics of lung cancer patients, and to explore whether they could act as valuable predictors to ameliorate lung cancer prognosis. A total of 1312 patients were eligible to be recruited. Lymphocyte percentage and neutrophil percentage were classified based on their reference ranges. Survival curves were determined using Kaplan–Meier method, and univariate and multivariate cox regression analyses were performed to identify the significant predictors. Decision curve analysis was used to evaluate the clinical benefit. The results of both training and validation cohorts indicated that lymphocyte percentage exhibited high correlation with clinical characteristics and metastasis of lung cancer patients. Both lymphocyte percentage and neutrophil percentage were closely associated with survival status (all p < 0.0001). Low lymphocyte percentage could act as an indicator of poor prognosis; it offered a higher clinical benefit when combined with the clinical characteristic model. Our findings suggested that pretreatment lymphocyte percentage served as a reliable predictor of lung cancer prognosis, and it was also an accurate response indicator in lung adenocarcinoma and advanced lung cancer. Measurement of lymphocyte percentage improved the clinical utility of patient characteristics in predicting mortality of lung cancer patients.

A Retrospective Study of Intrathecal Pemetrexed Combined With Systemic Therapy for Leptomeningeal Metastasis of Lung Cancer.

Objective This retrospective study aimed to investigate the clinical features of lung cancer patients with leptomeningeal metastasis (LM) and explore the clinical efficacy and tolerance of intrathecal pemetrexed (IP) combined with systemic antitumor therapy. Methods Thirty-four lung cancer patients (11 men, 23 women) with LM receiving IP at our hospital were retrospectively reviewed between August 2018 and December 2019. Identified cases showed either positive cerebrospinal fluid cytology or typical findings (leptomeningeal enhancement or ventricle broadening) upon imaging examination. Results Before the diagnosis of LM, 24 (70.6%) patients received EGFR-TKI therapy with or without other agents (antivascular therapy, or chemotherapy), 5 (14.7%) patients received chemotherapy, 1 (2.9%) patient received antivascular therapy, and 3 (8.8%) patients received ALK inhibitors. Fourteen (41.2%) patients did not change the systematic regimen at the beginning of IP, while 20 (58.8%) patients changed to antitumor agents. IP was administered for a median of 3 times (range, 1-12 times). The IP dose was 15, 20, 25, 30, and 40 mg in 8 (23.5%), 21 (58.8%), 2 (5.9%), 2 (5.9%), and 1 (5.9%) patient, respectively. In all IP dose levels, the major adverse events were myelosuppression and elevation of hepatic aminotransferases (EHA). Grade 1/2 myelosuppression occurred in 4 (11.8%) patients. Grade 1/2 EHA also occurred in 4 (11.8%) patients. Grades 3/4 adverse events were not observed. After IP and systematic therapy, the clinical manifestations related to LM in 26 (76.5%) patients improved. In the whole cohort, the median overall survival was 20 months. The median time from the initial IP administration until death or the last follow-up was 3.5 months. Conclusions IP showed controllable toxicity and good efficacy, prolonged the survival time, and improved the quality of life when combined with tailored systemic antitumor therapy in lung cancer patients.

Precision Medicine in Lung Cancer Theranostics: Paving the Way from Traditional Technology to Advance Era

Precision medicine for lung cancer theranostics is an advanced model combining prevention, diagnosis, and treatment for individual or specific population diseases to match individual patient differences. It involves collection and integration of genome, transcriptome, proteome, and metabolome features of lung cancer patients, combined with clinical characteristics. Subsequently, large data and artificial intelligence (AI) analysis have emerged to identify the most suitable therapeutic targets and personal treatment strategies for treatment of patients with lung cancer. We review the development and challenges associated with diagnosis and therapy of lung cancer from traditional technology, including immunotherapy prediction markers, liquid biopsy, surgery, and tumor immune microenvironment and patient-derived xenograft models, to AI in the era of precision medicine. AI has improved precision medicine and the predictive ability and accuracy of patient outcomes. Finally, we discuss some opportunities and challenges for lung cancer theranostics. Precision medicine in lung cancer can help us find the optimum treatment dose and time for a specific patient, which can advance the development of lung cancer therapeutics.

Benefits of precision medicine in lung cancer: experience from a single institution

Lung cancer remains the leading cause of cancer death worldwide and in China. Over the past two decades, targeted therapy and immunotherapy have improved the five-year survival rate of lung cancer, and precision medicine has played a great part in this progress. However, owing to the heterogeneity, complexity, and economic disparity, the usage of precision medicine is still low, which generally results in a poor prognosis. In view of the current bottlenecks, such as low early diagnosis rates and the poor prognosis of lung cancer patients, our team predicted and identified early diagnosis markers of lung cancer. We have described the genetic characteristics of lung cancer patients, identified potential treatment targets, and explored accurate treatment schemes for the disease. We have also promoted their application by conducting bioinformatic analysis, high-throughput sequencing, liquid biopsy, and improved FISH and other technologies. This has formed an integrated system for the precise diagnosis, treatment, and transformation of lung cancer research, obtaining good social benefits after their application.

Relationship between Hypercoagulable State and Circulating Tumor Cells in Peripheral Blood, Pathological Characteristics, and Prognosis of Lung Cancer Patients.

Objective To analyze the relationship between hypercoagulable state and circulating tumor cells (CTCs) in peripheral blood, pathological characteristics, and prognosis of lung cancer patients. Method A total of 148 patients with primary lung cancer diagnosed and treated in our hospital from January 2017 to January 2019 were selected as the research objects. According to the CTC test results, the patients were divided into CTC-positive group and CTC-negative group. Also, the coagulation index of patients was tested. According to the blood coagulation index test results, patients were divided into hypercoagulable group and non-hypercoagulable group. The relationship between hypercoagulable state and pathological characteristics of lung cancer patients was analyzed by single factor analysis and multiple logistic regression model. Kaplan–Meier survival curve was applied to analyze the relationship between hypercoagulable state and the prognosis of lung cancer patients. Results The platelets (PLTs), fibrinogen (FIB), D-dimer (D-D), and prothrombin time (PT) in CTC-positive group were significantly higher than those in CTC-negative group. There was no significant relationship between the patient's gender, smoking history, pathological type, and the hypercoagulable state of the patients. The proportion of patients aged 60 years or older, with TMN stage III or IV and lymph node metastasis, in the hypercoagulable group was significantly higher than that in the non-hypercoagulable group. Logistic regression analysis showed that there was an independent relationship between the patient's age, lymph node metastasis, and hypercoagulable state. As of January 2020, among the 148 patients with lung cancer follow-up, 5 patients were lost and 52 died. The median survival time of patients in the hypercoagulable group was 82 weeks, which was significantly lower than the 104 weeks in the nonhypercoagulable group. Conclusion There is a certain relationship between hypercoagulable state and CTC positive in lung cancer patients. There is an independent relationship between the patient's age, lymph node metastasis, and the hypercoagulable state. The median survival time of patients in the hypercoagulable group was significantly lower than that in the non-hypercoagulable group.

CT Guided TTNA and Core Biopsy in Suspected Lung Cancer, Review of Cases in Adam Malik General Hospital, Medan

ounds: The cytological and histopathological findings establish the type of lung cancer cells as the definitive diagnosis of lung cancer. This study aimed to determine the characteristics of lung cancer patients in terms of age, mean age, gender, staging, the proportion of lung cancer cells by cytologic examination of Transthoracic Needle Aspiration (TTNA) and histopathologic evaluation from CT-guided core biopsy. Method: This is a descriptive study involving 42 subjects diagnosed with lung cancer at H. Adam Malik Hospital Medan in 2016-2020 that met the inclusion criteria through consecutive sampling. Data was analysed using descriptive statistics for categorical variables. Results: Of 42 study subjects, the 60–71-year age group had the highest percentage of lung cancer (42.9%). Male (71.4%) was higher than female, the most common lung cancer staging was IVA (57.1%), and adenocarcinoma was found to be the most frequent type of lung cancer in both cytology (33.3%) and histopathology (31.0%). Conclusion: We concluded that core biopsy is superior in diagnosing lung cancer compared to TTNA.

Smoking-Related Characteristics of Lung Cancer Patients With Alcohol Use Problems

Objectives: This study was designed to investigate the smoking-related characteristics of lung cancer patients with alcohol use problem. Methods ： A total of 200 histologically confirmed lung cancer patients who had a current smoking status at the time of cancer diagnosis were recruited into this study. Demographic and smoking- related characteristics were assessed. Smoking-related characteristics, including smoking onset and duration, experiences of smoking cessation, Fagerstrom Test for Nicotine Dependence (FTND), and Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for tobacco use disorder, were assessed. The Korean version of Alcohol Use Disorders Identification Test (AUDIT-K) was used to classify the alcohol use problem group and the non-alcohol use problem group. Results ： Lung cancer patients with alcohol use problem smoked more number of cigarettes per day. Smoking cessation attempts, duration of the longest smoking cessation, and experiences of smoking cessation treatment did not differ between the two groups. The alcohol use problem group showed a higher FTND score and prevalence of severe tobacco use disorder. Conclusion : The results showed that lung cancer patients with alcohol use problem had more severe nicotine dependence. This implies that the alcohol use problem comorbid with lung cancer would interfere with smoking cessation trials and aggravate lung cancer. Detection and intervention for alcohol use problem in lung cancer patients would be beneficial for smoking cessation and longitudinal course of lung cancer.

Meta-analysis of Correlation between Peripheral Serum MIC-1 level and Lung Cancer

Lung cancer (LC) is a common malignant tumor with high morbidity and mortality. The development of new molecular markers and the early diagnosis of LC and the exploration of emerging targeted therapies are of great significance. Therefore, this study systematically evaluates the correlation between peripheral serum MIC-1 levels and LC. Search PubMed, Web of Science, Medline and other databases, the search time is from the establishment of the database to July 2021. The LC group included LC patients, the Non-cancer group included patients with benign lung diseases (BLD), and the control group included healthy people. The serum MIC-1 levels of LC group and control group, LC group and Non-cancer group were compared respectively, and the correlation between serum MIC-1 and clinical characteristics of LC patients was evaluated and analyzed, and the ROC curve of MIC-1 in prediction of LC. Finally, 5 articles were included, including 1179 patients with LC, 109 patients with BLD, and 1020 healthy people. Meta-analysis results: the level of MIC-1 in LC group was overtop that in healthy group, and the difference was obvious [SMD=1.97, 95%CI (1.35, 2.59), PC0.00001]. The level of MIC-1 in LC group was overtop that in Non-cancer group, and the difference was obvious [SMD=382.97,95%CI (313.74, 452.19), PC0.00001]. The descriptive evaluation analyzes the correlation between MIC-1 and the clinical characteristics of LC group, and the results show that MIC-1 has a certain correlation with the stage of LC group. The AUC of serum MIC-1 in the identification of LC group and the control group was greater than 0.5. The AUC value of MIC-1 in the diagnosis of LC was 0.851-0.906, and the best sensitivity range was 63.50%-99.00%. The best specificity is in the range of 70.4%-95.80%. The Meta-analysis indicated that the serum MIC-1 level in LC group is overtop that in BLD and healthy people, and has a obvious correlation with LC stage staging; and the ROC curve shows that it has important significance in the diagnosis and prognosis of LC.

Impact of coexistent preserved ratio impaired spirometry on the survival of patients with lung cancer: Analysis of data from the Korean Association for Lung Cancer Registry.

BackgroundPreserved ratio impaired spirometry (PRISm) is a common spirometric pattern that is associated with respiratory symptoms and higher mortality rates. However, the relationship between lung cancer and PRISm remains unclear. This study investigated the clinical characteristics of lung cancer patients with PRISm and the potential role of PRISm as a prognostic factor.MethodsWe retrospectively reviewed data collected from 2014 to 2015 in the Korean Association for Lung Cancer Registry. We classified all patients into three subgroups according to lung function as follows: normal lung function; PRISm (forced expiratory volume in 1 s [FEV1] < 80% predicted and FEV1/forced vital capacity [FVC] ≥ 0.7); and chronic obstructive pulmonary disease (COPD; FEV1/FVC < 0.7). In non–small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), the overall survival period was compared among the three subgroups. The prognostic factors were investigated using Cox regression analysis.ResultsOf the 3763 patients, 38.6%, 40.1%, and 21.3% had normal lung function, COPD, and PRISm, respectively. Patients with PRISm had poorer overall survival than those with COPD or normal lung function in NSCLC and SCLC (Mantel–Cox log‐rank test, p < 0.05). In the risk‐adjusted analysis, overall survival was independently associated with COPD (hazard ratio [HR] 1.209, p = 0.027) and PRISm (HR 1.628, p < 0.001) in NSCLC, but was only associated with PRISm (HR 1.629, p = 0.004) in SCLC.ConclusionsPRISm is a significant pattern of lung function in patients with lung cancer. At the time of lung cancer diagnosis, pre‐existing PRISm should be considered a predictive factor of poor prognosis.

Genomic features of lung cancer patients harboring germline mutations associated with hereditary cancer syndromes.

e20511 Background: Smoking and air pollution are the major causes of lung cancer; however, numerous studies have demonstrated that genetic factors also contribute to the development of lung cancer. Here, we reported an analysis of genomic features in 65 lung cancer patients with autosomal-dominant or autosomal-recessive inheritance of germline mutations. Methods: We retrospectively reviewed next-generation sequencing data of 26,904 lung cancer patients in a Chinese cohort. The germline mutation patterns, as well as the co-occurrence with somatic driver mutations were analyzed. Results: A total of 65 (0.24%) patients with heterozygous germline mutations associated with hereditary cancer syndromes were detected, including 27 (0.10%) patients with autosomal-dominant inheritance (BRCA1, BRCA2, RET and TP53) and 38 (0.14%) patients with autosomal-recessive inheritance (ATM, BLM, FANCA, FANCG, MUTYH, NBN, RECQL4 and WRN). Comparing to patients with autosomal-dominant inheritance (Age 56±17.8), patients with autosomal-recessive inheritance (Age 65±11.7, P = 0.009) were older, and there is no gender difference. Additionally, 66.7% (18/27) of patients with autosomal-dominant inheritance were identified co-mutated actionable variations, such as 12 patients harboring mutations in exon 18–21 of EGFR, 2 patients harboring ERBB2 exon 20 insertions, 3 patients harboring mutations in exon 2 of KRAS and 1 patient harboring EML4-ALK fusion. The coexistence of germline autosomal-dominant mutations and somatic driver mutations indicated that germline mutations have weak impact on lung cancer. Simultaneously, 52.6% (20/38) of patients with autosomal-recessive inheritance were identified co-mutated actionable variations, such as 15 EGFR+ patients, 2 ERBB2+ patients and 3 KRAS+ patients. And there was no significant difference in population frequency of co-mutated actionable variations between the two groups. Conclusions: In summary, studies on germline mutations of lung cancer patients may help to elucidate the etiology and mechanism of lung cancer, and may help for early detection and diagnosis, targeted therapy and improved prevention strategies.

Clinical, Tomographic and Histopathological Features of Lung Cancer Patients

In 2015, 61 patients diagnosed with lung cancer treated at the Radiology Service of “Dr. Juan Bruno Zayas Alfonso” Teaching General Hospital in Santiago de Cuba, were observed and conducted descriptive and cross-sectional studies to characterize them according to the variables of interest. The results were organized into frequency distributions and single-input and two-input tables were compiled to establish certain relationships between the variables. Male (55.7%), 60–69 age group (39.3%), history of chronic bronchitis in male and female (75.4%), cough as the main symptom (63.9%), peripheral localization (78.7%) and adenocarcinoma as the histological type (57.4%). At the time of diagnosis, most patients are at the last stage of the disease, so studies are recommended for all patients at risk.